18F-Fluorocholine Uptake by a Head and Neck Meningeal Inflammatory Pseudotumor.
Abstract F-Fluoro-ethyl-choline (F-FCH) PET/CT is widely used to study patients affected by prostate cancer. However, F-FCH may be taken-up by other neoplastic diseases, infections, and non-infective inflammatory processes. While this behavior may be an opportunity to study different diseases, on the other hand, this condition brings with it the source of error in the evaluation of the images. Here we present the case of a meningeal inflammatory pseudotumor evidenced by F-FCH. PMID: 31274616 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 7, 2019 Category: Cancer & Oncology Authors: Savelli G, Morassi M, Cobelli M, Stefanelli A, Zaniboni A Tags: Clin Nucl Med Source Type: research

Thyroid Incidentaloma on 18F-fluorocholine PET/CT and 68Ga-PSMA PET/CT Revealing a Medullary Thyroid Carcinoma.
det S Abstract A 66-year-old man with prostate cancer underwent F-fluorocholine PET/CT and thereafter Ga-labeled prostate-specific membrane antigen PET/CT to explore a rising prostate-specific antigen level. Both PET/CT studies showed a thyroid incidentaloma of the right lobe. Neck ultrasound confirmed the presence of a 16-mm right thyroid nodule. The serum calcitonin level was moderately increased at 25 ng/mL (
Source: Clinical Prostate Cancer - July 7, 2019 Category: Cancer & Oncology Authors: Ciappuccini R, Edet-Sanson A, Saguet-Rysanek V, Gauthé M, Bardet S Tags: Clin Nucl Med Source Type: research

Incidental Detection of a Radiation-Induced Soft-Tissue Sarcoma on 68Ga-PSMA PET/CT in a Patient Previously Treated for Prostate Cancer.
We describe the incidental detection of a radiation-induced undifferentiated soft-tissue sarcoma with increased uptake on Ga-labeled prostate-specific membrane antigen (PSMA) PET/CT in a prostate cancer patient previously treated with surgery and external-beam radiotherapy. Results were confirmed by histological analysis. Ga-PSMA is known to bind not only to PSMA-expressing prostate cancer cells but also to the neovasculature of various other solid tumors. A careful Ga-PSMA PET/CT review of previously irradiated areas is warranted so as not to miss radiation-induced sarcoma in prostate cancer patients. PMID: 31274636 ...
Source: Clinical Prostate Cancer - July 7, 2019 Category: Cancer & Oncology Authors: Plouznikoff N, Woff E, Artigas C, Alexiou J, Flamen P Tags: Clin Nucl Med Source Type: research

Epidemiological Determinants of Advanced Prostate Cancer in Elderly Men in the United States.
In this study, we examined the effects of individual-level and area-level characteristics on advanced prostate cancer diagnosis among Medicare eligible older men (ages 70+ years). We analyzed patients from the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database (2000-2007) linked to US Census and County Business Patterns data. Cluster-adjusted logistic regression models were used to quantify the effects of individual preventive health behavior, clinical and demographic characteristics, area-level health services supply, and socioeconomic characteristics on stage at diagnosis. The fully adjust...
Source: Clinical Prostate Cancer - July 4, 2019 Category: Cancer & Oncology Authors: Jayasekera J, Onukwugha E, Cadham C, Tom S, Harrington D, Naslund M Tags: Clin Med Insights Oncol Source Type: research

Membranous nephropathy and thrombotic microangiopathy secondary to metastatic prostate cancer after Iodine-125 prostate brachytherapy: A case report 
.
CONCLUSION: This case study was the first report of MN with TMA as manifestations in patients with prostate cancer after I-125 seeds implantation. We hypothesize that prostate cancer may cause MN and TMA, and the mechanism behind this relationship merits further study.
. PMID: 31262399 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 2, 2019 Category: Cancer & Oncology Authors: Yang L, Liang D, Cheng S, Ge Y Tags: Clin Nephrol Source Type: research

Predictive Significance of Androgen Receptor Splice Variant 7 in Patients With Metastatic Castration-Resistant Prostate Cancer: The PROPHECY Study.
PMID: 31265358 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 2, 2019 Category: Cancer & Oncology Authors: Dirix L Tags: J Clin Oncol Source Type: research

Dissecting Prognostic From Predictive Utility: Circulating AR-V7 Biomarker Testing for Advanced Prostate Cancer.
PMID: 31265359 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 2, 2019 Category: Cancer & Oncology Authors: Sharp A, Porta N, Lambros MBK, Welti JC, Paschalis A, Raj GV, Plymate SP, de Bono JS Tags: J Clin Oncol Source Type: research

Association of glutathione-S-transferase p1 gene promoter methylation and the incidence of prostate cancer: a systematic review and meta-analysis.
CONCLUSIONS: Methylation of the GSTP1 promoter may increase the risk of prostate cancer. This study may provide a strategic direction for prostate cancer research. Pending validation of these findings, the methylation of the GSTP1 promoter may be a potential biomarker to diagnose prostate cancer. PMID: 31263949 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 1, 2019 Category: Cancer & Oncology Authors: Zhou X, Jiao D, Dou M, Chen J, Li Z, Li Y, Liu J, Han X Tags: J Cancer Res Clin Oncol Source Type: research

N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.
Abstract Despite recent therapeutic advances, prostate cancer remains a leading cause of cancer-related death. A subset of castration resistant prostate cancers become androgen receptor (AR) signaling-independent and develop neuroendocrine prostate cancer (NEPC) features through lineage plasticity. These NEPC tumors, associated with aggressive disease and poor prognosis, are driven, in part, by aberrant expression of N-Myc, through mechanisms that remain unclear. Integrative analysis of the N-Myc transcriptome, cistrome and interactome using in vivo, in vitro and ex vivo models (including patient-derived organoids...
Source: Clinical Prostate Cancer - July 1, 2019 Category: Cancer & Oncology Authors: Berger A, Brady NJ, Bareja R, Robinson BD, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X, Hwang I, Bagadion AM, Sboner A, Elemento O, Paik J, Yu J, Barbieri CE, Dephoure N, Beltran H, Rickman DS Tags: J Clin Invest Source Type: research

Adjuvant Chemotherapy for High-Risk Localized Prostate Cancer: Time for Change or Need More Time to Change?
PMID: 31260643 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 1, 2019 Category: Cancer & Oncology Authors: Aragon-Ching JB Tags: J Clin Oncol Source Type: research

Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer.
Abstract BACKGROUND: Trefoil Factor 3 (TFF3) has been implicated in Prostate Cancer (PCa) progression. However, its prognostic value and association with other biomarkers have not been fully explored. We assessed the combined value of TFF3 and PTEN in two cohorts: one is managed surgically for localized PCa and the second is managed non-surgically by androgen deprivation therapy for advanced disease. DESIGN: 228 radical prostatectomies (RP) and 318 transurethral resection of prostate (TURP) samples were assessed by immunohistochemistry (IHC) for TFF3 and by IHC and fluorescent in situ hybridization (FISH) for...
Source: Clinical Prostate Cancer - July 1, 2019 Category: Cancer & Oncology Authors: Abou-Ouf H, Ghosh S, Box A, Palanisamy N, Bismar TA Tags: J Cancer Res Clin Oncol Source Type: research

HALFMOON TomoTherapy (Helical ALtered Fractionation for iMplant partial OmissiON): implant-sparing post-mastectomy radiotherapy reshaping the clinical target volume in the reconstructed breast.
Abstract PURPOSE: To report the dosimetric feasibility of the radiation technique HALFMOON (Helical ALtered Fractionation for iMplant partial OmissiON) for post-mastectomy radiation therapy (PMRT) in intermediate-high-risk breast cancer patients with implant-based immediate breast reconstruction, where the clinical target volume (CTV) does not include the whole implant (implant-sparing approach). METHODS: In the HALFMOON technique, the CTV consisted of skin, subcutaneous tissues, and pectoralis major muscle, excluding the implant, chest wall muscles, and rib plane. The HALFMOON plans were compared with conven...
Source: Clinical Prostate Cancer - July 1, 2019 Category: Cancer & Oncology Authors: Leonardi MC, Spoto R, Miglietta E, Trivellato S, La Rocca E, Luraschi R, Grosso P, De Lorenzi F, Fodor C, Dicuonzo S, Dell'Acqua V, Gerardi MA, Morra A, Francia CM, Rietjens M, Galimberti VE, Veronesi P, Orecchia R, Cattani F, Jereczek-Fossa BA Tags: J Cancer Res Clin Oncol Source Type: research

Health-related quality of life of  exposed versus non-exposed androgen deprivation therapy patients with prostate cancer: a cross-sectional study.
Conclusions The quality of life of patients with all-stages prostate cancer differs significantly between androgen deprivation therapy users and non-androgen deprivation therapy users. The HRQoL for androgen deprivation therapy users is worse than for the non-androgen deprivation therapy users. Additionally, the symptoms are the key determinants of the quality of life. PMID: 31240550 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - June 25, 2019 Category: Cancer & Oncology Authors: Huang YT, Li CC, Chou YH, Ke HL, Chen CY Tags: Int J Clin Pharm Source Type: research

PI-RADS version 2.1: one small step for prostate MRI.
Abstract Multiparametric (mp) prostate magnetic resonance imaging (MRI) is playing an increasingly prominent role in the diagnostic work-up of patients with suspected prostate cancer. Performing mpMRI before biopsy offers several advantages including biopsy avoidance under certain clinical circumstances and targeting biopsy of suspicious lesions to enable the correct diagnosis. The success of the technique is heavily dependent on high-quality image acquisition, interpretation, and report communication, all areas addressed by previous versions of the Prostate Imaging-Reporting and Data System (PI-RADS) recommendati...
Source: Clinical Prostate Cancer - June 22, 2019 Category: Cancer & Oncology Authors: Barrett T, Rajesh A, Rosenkrantz AB, Choyke PL, Turkbey B Tags: Clin Radiol Source Type: research

68Ga-PSMA-617 Compared With 68Ga-RM2 and 18F-FCholine PET/CT for the Initial Staging of High-Risk Prostate Cancer.
gat C Abstract Ga-labeled prostate-specific membrane antigen inhibitors and Ga-labeled gastrin-releasing peptide receptor antagonists showed interesting results for staging biochemically recurrent prostate cancer. In this case, Ga-prostate-specific membrane antigen-617 PET/CT, Ga-RM2 PET/CT, and F-choline PET/CT were performed in a patient (66-year-old man, prostate-specific antigen = 6.7 ng/mL) with biopsy-proven Gleason 9 (5 + 4) prostate cancer, candidate for radical prostatectomy and lymph node dissection. PMID: 31246685 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - June 21, 2019 Category: Cancer & Oncology Authors: Schollhammer R, de Clermont Gallerande H, Robert G, Yacoub M, Vimont D, Hindié E, Fernandez P, Morgat C Tags: Clin Nucl Med Source Type: research

Low 68Ga-PSMA PET/CT Uptake in Chronic Intramuscular Nodular Fasciitis.
We describe herein a case of chronic nodular fasciitis of the left triceps muscle with a low Ga-labeled prostate-specific membrane antigen (PSMA) ligand uptake on PET/CT. Ga-PSMA ligands bind to PSMA-expressing prostate cancer cells, but uptake has also been demonstrated in other solid neoplasms and various benign lesions. Nodular fasciitis should be included in the differential diagnosis of soft tissue lesions with variable Ga-PSMA uptake. PMID: 31246686 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - June 21, 2019 Category: Cancer & Oncology Authors: Plouznikoff N, Artigas C, Karfis I, Flamen P Tags: Clin Nucl Med Source Type: research

Multiple Solitary Plasmacytomas With Multifocal Bone Involvement Diagnosed With 68Ga-Prostate-Specific Membrane Antigen PET/CT.
Abstract A 63-year-old man with elevated prostate-specific antigen serum levels and enlarged prostate gland underwent ultrasound-guided transrectal biopsy, which did not reveal any evidence of malignancy. In order to help guidance of repeat biopsy, Ga-prostate-specific membrane antigen-targeted ligand PET (PSMA PET/CT) was ordered. PET/CT scan showed no abnormal PSMA expression within the prostate gland. There were, however, multiple PSMA-expressing osteolytic lesions throughout the axial skeleton. Bone lesion biopsy obtained for final workup revealed multiple solitary plasmacytomas with multifocal bone involvemen...
Source: Clinical Prostate Cancer - June 21, 2019 Category: Cancer & Oncology Authors: Alabed YZ Tags: Clin Nucl Med Source Type: research

Validity of the Patient-Reported Outcome Measurement Information System (PROMIS) Sexual Interest and Satisfaction Measures in Men Following Radical Prostatectomy.
Abstract PURPOSE: Patient-reported outcomes after radical prostatectomy have focused on erectile function. To date, no studies have validated the Patient-Reported Outcome Measurement Information System (PROMIS) Sexual Interest and Satisfaction single item measures in patients with prostate cancer, nor have studies examined how these measures relate to erectile function. In addition, data are lacking with regard to the clinical responsiveness of these measures to treatment. We sought to validate and examine the clinical utility of these measures in men after radical prostatectomy. PATIENTS AND METHODS: We iden...
Source: Clinical Prostate Cancer - June 20, 2019 Category: Cancer & Oncology Authors: Agochukwu NQ, Wittmann D, Boileau NR, Dunn RL, Montie JE, Kim T, Miller DC, Peabody J, Carlozzi NE, Michigan Urological Surgery Improvement Collaborative Tags: J Clin Oncol Source Type: research

Prostate Radiotherapy in India: Evolution, Practice and Challenges in the 21st Century.
Abstract The practice of prostate radiotherapy is evolving rapidly while there is an increase in the incidence of prostate cancer in India. Here, the diverse socioeconomic milieu and varied healthcare delivery models interact to exert a significant influence on the adoption of new technologies and evidence emerging from the Western world. Using a targeted cross-country survey of radiation oncologists, this article captures the changing trends in prostate imaging, conformal techniques, dose escalation, hypofractionation, stereotactic ablation and prostate brachytherapy in the context of practice patterns in the Wes...
Source: Clinical Prostate Cancer - June 19, 2019 Category: Cancer & Oncology Authors: Murthy V, Mallick I, Arunsingh M, Gupta P Tags: Clin Oncol (R Coll Radiol) Source Type: research

Impact of daily soft-tissue image guidance to prostate on pelvic lymph node (PLN) irradiation for prostate patients receiving SBRT.
CONCLUSIONS: The 5 mm margin covered ~75% of fractions receiving PLN irradiation with SBRT, daily CBCT and fiducial-guided setup. The dosimetric impact on PLN coverage was significant in 19% of fractions or 25% of patients. A larger translational shift was due to variation in rectal volume and changes in COM position of the bladder and rectum. A consistent bladder positioning and/or rectum filling compared with presimulation volume were essential for adequate coverage of PLN in a hypofractionated treatment regime. PMID: 31206236 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - June 17, 2019 Category: Cancer & Oncology Authors: Tyagi N, Hipp E, Cloutier M, Charas T, Fontenla S, Mechalakos J, Hunt M, Zelefsky M Tags: J Appl Clin Med Phys Source Type: research

Radiotherapy Quality Assurance for the CHHiP Trial: Conventional Versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy in Prostate Cancer.
CONCLUSION: Overall, quality assurance results were satisfactory and the CHHiP quality assurance programme contributed to the success of the trial by auditing radiotherapy treatment planning and protocol compliance. Quality assurance supported the introduction of IMRT in UK centres, giving additional confidence and external review of IMRT where it was a newly adopted technique. PMID: 31201110 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - June 11, 2019 Category: Cancer & Oncology Authors: Naismith O, Mayles H, Bidmead M, Clark CH, Gulliford S, Hassan S, Khoo V, Roberts K, South C, Hall E, Dearnaley D, CHHiP Investigators Tags: Clin Oncol (R Coll Radiol) Source Type: research

Cancer treatment and survivorship statistics, 2019.
Abstract The number of cancer survivors continues to increase in the United States because of the growth and aging of the population as well as advances in early detection and treatment. To assist the public health community in better serving these individuals, the American Cancer Society and the National Cancer Institute collaborate every 3 years to estimate cancer prevalence in the United States using incidence and survival data from the Surveillance, Epidemiology, and End Results cancer registries; vital statistics from the Centers for Disease Control and Prevention's National Center for Health Statistics;...
Source: Clinical Prostate Cancer - June 11, 2019 Category: Cancer & Oncology Authors: Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL Tags: CA Cancer J Clin Source Type: research

Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis.
Abstract Background: Hypertension is one of the major side effects associated with abiraterone in the treatment of advanced prostate cancer. The specific contribution of abiraterone to hypertension has not been defined. We performed a systematic review and meta-analysis of randomized clinical trials to determine its overall risk. Methods: Databases including Pubmed (up to July 2018) and Google scholar (up to July 2018) were searched to identify relevant studies. Eligible studies were prospective randomized clinical trials with prostate cancer treated with abiraterone and prednisone. The incidence and relative...
Source: Clinical Prostate Cancer - June 8, 2019 Category: Cancer & Oncology Authors: Zhu X, Wu S Tags: Clin Hypertens Source Type: research

Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone.
CONCLUSION: The selective CatK inhibitor may prevent the establishment and progression of PCa in bone, thus making it a novel therapeutic approach for advanced PCa. PMID: 31172267 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - June 6, 2019 Category: Cancer & Oncology Authors: Liang W, Wang F, Chen Q, Dai J, Escara-Wilke J, Keller ET, Zimmermann J, Hong N, Lu Y, Zhang J Tags: J Cancer Res Clin Oncol Source Type: research

Comparison of PIRADS 3 lesions with histopathological findings after MRI-fusion targeted biopsy of the prostate in a real world-setting.
CONCLUSIONS: PIRADS 3 lesion indicates an equivocal likelihood of significant prostate cancer. In our series the overall PCa detection rate was 26.8% and 14.6% for clinically significant cancer in PIRADS 3 lesions. This evokes the question, if PIRADS 3 lesions could be surveilled only. The findings should be confirmed in a larger series. PMID: 30562897 [PubMed - indexed for MEDLINE] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - June 5, 2019 Category: Cancer & Oncology Authors: Schlenker B, Apfelbeck M, Armbruster M, Chaloupka M, Stief CG, Clevert DA Tags: Clin Hemorheol Microcirc Source Type: research

Treatment-Related Toxicity Using Prostate-Only Versus Prostate and Pelvic Lymph Node Intensity-Modulated Radiation Therapy: A National Population-Based Study.
CONCLUSION: Including PLNs in radiation fields for high-risk or locally advanced prostate cancer is not associated with increased GI or GU toxicity at 3 years. Additional follow-up is required to answer questions about its impact on late GU toxicity. Results from ongoing trials will provide insight into the anticancer effectiveness of PLN irradiation. PMID: 31163009 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - June 4, 2019 Category: Cancer & Oncology Authors: Parry MG, Sujenthiran A, Cowling TE, Nossiter J, Cathcart P, Clarke NW, Payne H, van der Meulen J, Aggarwal A Tags: J Clin Oncol Source Type: research

Optimal sampling of pelvic lymphadenectomy specimens following radical prostatectomy: is complete tissue submission justified?
Abstract There is currently no consensus among pathologists on the optimal method of sampling pelvic lympadenectomy specimens (PLND) in prostate cancer. We evaluated the impact of complete PLND submission on lymph node (LN) yield, detection of metastasis and laboratory workload in a series of 141 cases. Following isolation of grossly identifiable LNs/potential LNs, the remaining fatty tissue was embedded in toto. Complete PLND submission increased median LN yield from 10 (1-42) to 17 (3-57). Metastatic deposits were identified in nine non-palpable LNs, which altered the pN category in four cases (3%). The primary ...
Source: Clinical Prostate Cancer - June 1, 2019 Category: Cancer & Oncology Authors: Ni Mhaolcatha S, Power E, Mayer N, Prendeville S Tags: J Clin Pathol Source Type: research

18F-Fluorocholine Uptake by a Head and Neck Meningeal Inflammatory Pseudotumor.
Abstract F-Fluoro-ethyl-choline (F-FCH) PET/CT is widely used to study patients affected by prostate cancer. However, F-FCH may be taken-up by other neoplastic diseases, infections, and non-infective inflammatory processes. While this behavior may be an opportunity to study different diseases, on the other hand, this condition brings with it the source of error in the evaluation of the images. Here we present the case of a meningeal inflammatory pseudotumor evidenced by F-FCH. PMID: 31162252 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - June 1, 2019 Category: Cancer & Oncology Authors: Savelli G, Morassi M, Cobelli M, Stefanelli A, Zaniboni A Tags: Clin Nucl Med Source Type: research

Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy.
We report here an mCRPC patient with lung, lymph nodes, and extensive bone metastases, who underwent Lu-PRLT and had excellent response to the treatment and complete regression of lung metastases after Lu-PRLT. PMID: 31162261 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - June 1, 2019 Category: Cancer & Oncology Authors: Zhang J, Kulkarni HR, Singh A, Baum RP Tags: Clin Nucl Med Source Type: research

Report of the forth Asian Prostate Cancer (A-CaP) study meeting.
Abstract The Asian Prostate Cancer (A-CaP) Study is an Asia-wide prospective registry study for surveying the treatment outcome of prostate cancer patients who have received a histopathological diagnosis. The study aims to clarify the clinical situation for prostate cancer in Asia and use the outcomes for the purposes of international comparison. Following the first meeting in Tokyo on December 2015, the second meeting in Seoul, Korea 2016, the third meeting in Chiang Mai, Thailand, on October 2017, the fourth meeting was held in Seoul, again on August 2018 with the participation of members and collaborators from ...
Source: Clinical Prostate Cancer - May 31, 2019 Category: Cancer & Oncology Authors: Youl Lee J, Taniguchi T, Zhang K, Ng CF, Hakim L, Umbas R, Kim CS, Chung BH, Kim WJ, Aik Ong T, Lim J, Akaza H Tags: Jpn J Clin Oncol Source Type: research

Favorable long-term oncological and urinary outcomes of incidental prostate cancer following holmium laser enucleation of the prostate.
Abstract The aim of the present study was to investigate the impact of incidental prostate cancer (IPCa), which was diagnosed by holmium laser enucleation of the prostate (HoLEP), on long-term oncological and functional outcomes. A total of 482 patients who underwent HoLEP for benign prostatic hyperplasia (BPH) between 2008 and 2016 at our institution were retrospectively reviewed. We defined IPCa as prostate cancer (PCa) according to the enucleated tissue of transitional zone. Therefore, 64 patients were excluded for the following reasons: Prostate-specific antigen (PSA) ≥4.0 ng/ml and no prostate biopsy (n=46...
Source: Clinical Prostate Cancer - May 1, 2019 Category: Cancer & Oncology Authors: Tominaga Y, Sadahira T, Mitsui Y, Maruyama Y, Tanimoto R, Wada K, Munemasa S, Kusaka N, Nishiyama Y, Kurashige T, Nasu Y, Hayata S Tags: Mol Clin Oncol Source Type: research

Robotic treatment of giant adrenal myelolipoma: A case report and review of the literature.
In conclusion, robotic surgery allows performing partial adrenalectomy with a lower risk of bleeding and with preservation of healthy adrenal tissue, which is of paramount importance for the patient as it reduces recovery time and the need for medical substitution therapy. PMID: 31007910 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 24, 2019 Category: Cancer & Oncology Authors: Cochetti G, Paladini A, Boni A, Silvi E, Tiezzi A, De Vermandois JAR, Mearini E Tags: Mol Clin Oncol Source Type: research

Multiple primary malignancies of six organs in a Japanese male patient: A case report.
We report the case of a 79-year-old male with multiple primary malignancies of three histological types in six different organs: Stomach, prostate, colon, urinary bladder, facial skin and pancreas, in chronological order. The first malignancy was upper gastric cancer diagnosed in 1998. The second and third malignancies were prostate cancer and ascending colon cancer, which were diagnosed in 2010. The fourth malignancy was bladder cancer diagnosed in 2011. The fifth and sixth malignancies were squamous cell skin cancer of the right cheek and intraductal papillary mucinous carcinoma (IPMC), respectively, diagnosed in 2014. T...
Source: Clinical Prostate Cancer - April 12, 2019 Category: Cancer & Oncology Authors: Muto Y, Suzuki K, Kato T, Ichida K, Takayama Y, Fukui T, Kakizawa N, Watanabe F, Kaneda Y, Noda H, Rikiyama T Tags: Mol Clin Oncol Source Type: research

Predictive factors for short-term biochemical recurrence-free survival after robot-assisted laparoscopic radical prostatectomy in high-risk prostate cancer patients.
CONCLUSIONS: PSA level > 20 ng/mL and/or presence of the Gleason pattern 5 component on biopsy are predictive factors for early biochemical recurrence after robot-assisted laparoscopic radical prostatectomy in high-risk prostate cancer patients. We considered that these patients require a combined modality therapy to improve their prognosis. PMID: 30972506 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 10, 2019 Category: Cancer & Oncology Authors: Kanehira M, Takata R, Ishii S, Ito A, Ikarashi D, Matsuura T, Kato Y, Obara W Tags: Int J Clin Oncol Source Type: research

Effect of bisphosphonates on overall survival in subgroups of patients with prostate cancer.
Abstract Adjuvant therapy with bisphosphonates in prostate cancer is effective in improving bone mineral density and thus reducing fractures and skeletal-related events. We analyzed the effect of bisphosphonates on overall survival (OS) in subgroups of patients with prostate cancer. A systematic literature search was conducted of the PubMed database and the bibliographies of related studies. The long-term OS rates were extracted from every eligible trial. The hazard ratio (HR) was pooled with the fixed effects model, and preplanned subgroup analyses were performed. The search yielded 112 articles, of which 10 arti...
Source: Clinical Prostate Cancer - April 8, 2019 Category: Cancer & Oncology Authors: Wu C, Chen W, Wu J, Zhang X, Huang X, Lin R, Zhu B, Jiang H Tags: Clin Exp Metastasis Source Type: research

The prognosis value of EphA3 and the androgen receptor in prostate cancer treated with radical prostatectomy.
This study aimed to preliminarily assess the relationship between erythropoietin-producing hepatocellular carcinoma receptor A3 (EphA3) and androgen receptor (AR) protein expression levels and prognosis in prostate cancer (PCa) to better understand the role of EphA3 in the prognosis and progression of PCa. MATERIALS: We investigated the expression of EphA3 and AR in human PCa by immunohistochemistry. RESULTS: EphA3 and AR were both significantly upregulated in PCa, with expression mainly localized to the nucleus. A high level of AR expression was found in 48.4% of 64 tumor samples, which was significantly more th...
Source: Clinical Prostate Cancer - April 8, 2019 Category: Cancer & Oncology Authors: Duan X, Xu X, Yin B, Hong B, Liu W, Liu Q, Tao Z Tags: J Clin Lab Anal Source Type: research

Prostate artery embolisation: an all-comers, single-operator experience in 159 patients with lower urinary tract symptoms, urinary retention, or haematuria with medium-term follow-up.
CONCLUSION: PAE is safe and effective in the management of symptomatic BPH. Patients with the highest baseline IPSS and reduction in prostate volume on first post-PAE MRI are likely to derive most benefit from embolisation. PMID: 30955835 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 5, 2019 Category: Cancer & Oncology Authors: Thulasidasan N, Kok HK, Elhage O, Clovis S, Popert R, Sabharwal T Tags: Clin Radiol Source Type: research

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study.
CONCLUSIONS: At the 3-year follow-up, the efficacy and safety results of CheckMate 025 are generally consistent in the global and the Japanese populations. PMID: 30941424 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 3, 2019 Category: Cancer & Oncology Authors: Tomita Y, Fukasawa S, Shinohara N, Kitamura H, Oya M, Eto M, Tanabe K, Saito M, Kimura G, Yonese J, Yao M, Uemura H Tags: Jpn J Clin Oncol Source Type: research

Prevalence of Solid Neoplasms Diagnosed Between the Years of 2011 to 2016 and Oncologically Treated at the University Hospital of Santa Maria.
Conclusion: Most of the data obtained are consistent with the Brazilian reality, not identifying any peculiar characteristic of this region of the study worthy of note, except for the difference in the prevalence of some types of cancer, a fact that deserves further studies. There were also no discrepancies in a regional analysis. Along with this work, it was possible to demonstrate the cancer situation and the profile of oncology patients attended at a reference center for 41 municipalities, mainly in the central region of Rio Grande do Sul state, which may be useful in the elaboration of public policies to modify the pro...
Source: Clinical Prostate Cancer - April 1, 2019 Category: Cancer & Oncology Authors: da Silva FB, Binato M, da Silva JT, Marques CT, Ribeiro TA Tags: J Clin Med Res Source Type: research

Intensity-modulated radiation therapy for elderly patients (aged ≥75 years) with localized prostate cancer: Comparison with younger patients (aged < 75 years).
Intensity-modulated radiation therapy for elderly patients (aged ≥75 years) with localized prostate cancer: Comparison with younger patients (aged
Source: Clinical Prostate Cancer - April 1, 2019 Category: Cancer & Oncology Authors: Tanaka H, Nakashima Y, Ito M, Yamaguchi T, Esaki K, Kamei S, Ishihara S, Hayashi M, Ogawa S, Goshima S, Matsuo M Tags: Mol Clin Oncol Source Type: research

Minimally Invasive Techniques in Urology.
Abstract Urologists were early adopters of minimally invasive, specifically robotic, techniques for cancer surgery. The current trends show increasing adoption of robotic surgery for renal, bladder, and prostate cancer. Several randomized controlled trials show that robotic urologic surgery has outcomes that are at least as good as, if not superior to, open surgery. PMID: 30851832 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 12, 2019 Category: Cancer & Oncology Authors: Eswara JR, Ko DS Tags: Surg Oncol Clin N Am Source Type: research

A Proposed Efficacious Treatment with Clioquinol (Zinc Ionophore) and Cabergoline (Prolactin Dopamine Agonist) for the Treatment of Terminal Androgen-independent Prostate Cancer. Why and How?
Abstract All cases of prostate cancer exhibit the hallmark condition of marked decrease in zinc in malignancy compared to the high zinc levels in the normal and benign prostate. There exists no reported corroborated case of prostate cancer in which malignancy exhibits the high zinc levels that exist in the normal prostate acinar epithelium. The decrease in zinc is achieved by the downregulation of ZIP1 zinc transporter, which prevents the uptake and accumulation of cytotoxic zinc levels. Thus, prostate cancer is a "ZIP1-deficient" malignancy. Testosterone and prolactin are the major hormones that similar...
Source: Clinical Prostate Cancer - March 6, 2019 Category: Cancer & Oncology Authors: Costello LC, Franklin RB Tags: J Clin Res Oncol Source Type: research

Correction to: Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration.
Abstract The original article can be found online. PMID: 30826960 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 2, 2019 Category: Cancer & Oncology Authors: Shigeta K, Kosaka T, Hongo H, Yanai Y, Matsumoto K, Morita S, Mizuno R, Shinojima T, Kikuchi E, Oya M Tags: Int J Clin Oncol Source Type: research

18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA ≤ 1 ng/mL After Definitive Primary Treatment.
CONCLUSIONS: Detection of recurrent prostate cancer using F-fluciclovine PET/CT is possible in patients with low but rising PSA levels of 1 ng/mL or less. In such patients, local and nodal recurrences are more common than distant metastasis, and Gleason score greater than 7 is associated with positive scan results. PMID: 30589673 [PubMed - indexed for MEDLINE] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 1, 2019 Category: Cancer & Oncology Authors: England JR, Paluch J, Ballas LK, Jadvar H Tags: Clin Nucl Med Source Type: research

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.
CONCLUSION: Whereas PROSTVAC was safe and well tolerated, it had no effect on OS or AWE in metastatic castration-resistant prostate cancer. Combination therapy is currently being explored in clinical trials. PMID: 30817251 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 28, 2019 Category: Cancer & Oncology Authors: Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, Pook DW, Rathenborg P, Flaig TW, Carles J, Saad F, Shore ND, Chen L, Heery CR, Gerritsen WR, Priou F, Langkilde NC, Novikov A, Kantoff PW Tags: J Clin Oncol Source Type: research

The role of heterogeneous environment and docetaxel gradient in the emergence of polyploid, mesenchymal and resistant prostate cancer cells.
Abstract The ability of a population of PC3 prostate epithelial cancer cells to become resistant to docetaxel therapy and progress to a mesenchymal state remains a fundamental problem. The progression towards resistance is difficult to directly study in heterogeneous ecological environments such as tumors. In this work, we use a micro-fabricated "evolution accelerator" environment to create a complex heterogeneous yet controllable in-vitro environment with a spatially-varying drug concentration. With such a structure we observe the rapid emergence of a surprisingly large number of polyploid giant cancer ...
Source: Clinical Prostate Cancer - February 27, 2019 Category: Cancer & Oncology Authors: Lin KC, Torga G, Sun Y, Axelrod R, Pienta KJ, Sturm JC, Austin RH Tags: Clin Exp Metastasis Source Type: research

Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.
CONCLUSION: Neoadjuvant hormone therapy followed by RP in locally advanced prostate cancer resulted in favorable pathologic responses in some patients, with a trend toward improved pathologic outcomes with ELAP. Longer follow-up is necessary to evaluate the impact of therapy on recurrence rates. The potential association of ERG and PTEN alterations with worse outcomes warrants additional investigation. PMID: 30811282 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 27, 2019 Category: Cancer & Oncology Authors: McKay RR, Ye H, Xie W, Lis R, Calagua C, Zhang Z, Trinh QD, Chang SL, Harshman LC, Ross AE, Pienta KJ, Lin DW, Ellis WJ, Montgomery B, Chang P, Wagner AA, Bubley GJ, Kibel AS, Taplin ME Tags: J Clin Oncol Source Type: research

Clinical interpretation of prostate-specific antigen values: Type of applied cut-off value exceeds methods bias as the major source of variation.
CONCLUSIONS: This study shows that the differences in cut-off values exceed the method-specific differences. These results emphasize the need for (inter)national harmonization/standardization programmes including cut-off values to allow for laboratory-independent clinical decision-making. PMID: 30798616 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 24, 2019 Category: Cancer & Oncology Authors: Klinkenberg LJ, Lentjes EG, Boer AK Tags: Ann Clin Biochem Source Type: research

Statins Use and the Risk of Prostate Cancer in Ischemic Heart Disease Patients in Taiwan.
This article is protected by copyright. All rights reserved. PMID: 30801679 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 22, 2019 Category: Cancer & Oncology Authors: Ho W, Choo DW, Wu YJ, Chan TF, Lin ZF Tags: Clin Pharmacol Ther Source Type: research

Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart.
PMID: 30794477 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 22, 2019 Category: Cancer & Oncology Authors: Vapiwala N, Hofman MS, Murphy DG, Williams S, Sweeney C Tags: J Clin Oncol Source Type: research